Salarius Pharmaceuticals, Inc. (NASDAQ:SLRX) has announced the resumption of patient enrollment in a Phase 1/2 clinical trial evaluating seclidemstat combined with azacitidine for myelodysplastic ...
A novel approach developed by scientists, including Rice University chemist James Tour, could transform treatment for ...
Being evaluated for the treatment of metastatic colorectal cancer, the combination regimen achieved an objective response ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback